PTTG mRNA expression in primary breast cancer: A prognostic marker for lymph node invasion and tumor recurrence

Breast

Volumn 13, Issue 1, 2004, Pages 80-81

  Solbach, Christine ^a   Roller, Marc ^a   Fellbaum, Christian ^a   Nicoletti, Maria ^a   Kaufmann, Manfred ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; ONCOPROTEIN; PITUITARY TUMOR TRANSFORMING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER INFILTRATION; CANCER RECURRENCE; CLINICAL FEATURE; CLINICAL OBSERVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE;

EID: 1242297832     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2003.09.008     Document Type: Article

References (6)

1. Pei L, Melmed S. Isolation and characterization of a pituitary tumor transforming gene (PTTG). Mot Endocrinol 1997;11: 433-41.
2. Zou H, McGarry J, Bernal T, Kirschner MW. Identification of a vertebrate sister chromatid separation inhibitor involved in transformation and tumorigenesis. Science 1999;285:418-21.
3. Bernal JA, Luna R, Espina A, Lazaro I, Ramos-Morales F, Romero F, Arias C, Silva A, Tortolero M, Pintor-Toro JA. Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat Genet 2002;32: 222-4.
4. Zhou Y, Mehta KR, Choi AP, Scolavino S, Zhang X. DNA damage-induced inhibition of securin expression is mediated by p53. J Biol Chem 2003;278:462-70.
5. Pei L. Identification of c-Myc as a down-stream target for pituitary tumor-transforming gene. J Biol Chem 2000;276: 8484-91.
6. Solbach C, Roller M, Budischewski K, Loibl S, Nicoletti M, Stegmueller M, Kaufmann M. EGF-R and Her/2neu overexpressing tumors, independent collectives for treatment of breast cancer by specific monoclonal antibody therapy. J Cancer Res Clin Oncol 2003;129:250-1.